Abstract：
:Lobectomy remains the standard procedure for early-stage non small-cell lung cancer (NSCLC). Advances in minimally invasive surgery allow lobectomy to be performed by videothoracoscopy (VATSLOBE). The objective of this study was to compare open thoracotomy (OPENLOBE) to VATSLOBE in the treatment of early-stage NSCLC. A retrospective review over a 6-year period at a single tertiary care center identified 31 patients treated by VATSLOBE. A comparison was made with 31 patients undergoing OPENLOBE during the same time period. The cases were matched for age, pulmonary function testing, tumor size, and comorbidities. The VATSLOBE technique was carried out using four 1 cm thoracoports, one of which was enlarged to a 4-6 cm access incision for lobe retrieval. OPENLOBE was performed by standard posterolateral thoracotomy. The VATSLOBE group had a longer operative time (214.03 min) compared to OPENLOBE (140.67 min). There was no difference in the extent of lymph node dissection or in morbidity between the two groups. VATSLOBE patients had their chest tubes removed earlier (4.77 vs. 8.16 days) and stayed in the hospital for a shorter time (7.07 vs. 11.94 days) compared to OPENLOBE patients. In this retrospective review, lobectomy performed by the videothoracoscopic approach was comparable to OPENLOBE in terms of lymph node dissection, morbidity, and long-term survival. VATSLOBE had the advantages of a shorter hospital stay and fewer days with a chest tube. Minimally invasive surgery for early-stage lung cancer should be further investigated in multi-institutional controlled trials.
journal_name
Clin Lung Cancerjournal_title
Clinical lung cancerauthors
Luketich JD,Meehan MA,Landreneau RJ,Christie NA,Close JM,Ferson PF,Keenan RJ,Belani CPdoi
10.3816/clc.2000.n.018keywords:
subject
Has Abstractpub_date
2000-08-01 00:00:00pages
56-60; discussion 61issue
1eissn
1525-7304issn
1938-0690pii
S1525-7304(11)70623-4journal_volume
2pub_type
杂志文章abstract：BACKGROUND:While lepidic-predominant lung adenocarcinomas are known to have better outcomes than similarly sized solid tumors, the impact of smaller noninvasive foci within predominantly solid tumors is less clearly characterized. We tested the hypothesis that lung adenocarcinomas with even a small ground-glass opacity...
journal_title：Clinical lung cancer
pub_type： 杂志文章
doi：10.1016/j.cllc.2017.06.020
更新日期：2018-01-01 00:00:00
abstract：INTRODUCTION:A recent review of phase I trials suggests that participation in these trials can be associated with clinical benefit and the rate of drug-related deaths is low. We conducted an analysis of the Cancer Therapy Evaluation Program (CTEP)-sponsored phase I trials to assess the outcomes of lung cancer patients ...
journal_title：Clinical lung cancer
pub_type： 杂志文章
doi：10.1016/j.cllc.2011.03.022
更新日期：2011-07-01 00:00:00
abstract：BACKGROUND:The safety and efficacy of platinum-based combination chemotherapy for elderly patients with advanced non-small-cell lung cancer (NSCLC) remains unclear. We conducted phase I and phase II trials of a combination of vinorelbine and carboplatin for patients ≥75 years of age and with advanced NSCLC. PATIENTS A...
journal_title：Clinical lung cancer
pub_type： 杂志文章
doi：10.1016/j.cllc.2011.11.007
更新日期：2012-09-01 00:00:00
abstract：BACKGROUND:This study assesses the predictive and prognostic roles of serum soluble intercellular adhesion molecule-1 (sICAM-1) and vascular endothelial growth factor (VEGF) during chemotherapy in patients with advanced non-small-cell lung cancer (NSCLC). PATIENTS AND METHODS:Changes in serum levels of sICAM-1 and VEG...
journal_title：Clinical lung cancer
pub_type： 杂志文章
doi：10.1016/j.cllc.2011.03.009
更新日期：2011-03-01 00:00:00
abstract：BACKGROUND:Many patients diagnosed with stage IIIB (AJCC sixth edition; T4, N3, or both; no pleural effusion) non-small-cell lung cancer (NSCLC) are treated with curative intent, despite a low cure rate. Guidelines are required to help select patients for radical therapy so that the patients with little chance of cure ...
journal_title：Clinical lung cancer
pub_type： 杂志文章
doi：10.1016/j.cllc.2013.12.007
更新日期：2014-05-01 00:00:00
abstract：:Viruses capable of inducing lysis of malignant cells through their replication process are known as "oncolytic" viruses. Clinical trials in oncology have been performed with oncolytic viruses for nearly fifty years. Both systemic and intratumoral routes of administration have been explored. Toxicity has generally been...
journal_title：Clinical lung cancer
pub_type： 杂志文章
doi：10.3816/clc.1999.n.003
更新日期：1999-08-01 00:00:00
abstract：BACKGROUND:Obtaining a tissue diagnosis has traditionally been standard practice before initiating therapy for early-stage non-small-cell lung cancer (NSCLC). In several recent studies from Europe and Asia, a substantial proportion of patients have received stereotactic body radiation therapy (SBRT) based only on the i...
journal_title：Clinical lung cancer
pub_type： 杂志文章
doi：10.1016/j.cllc.2014.04.001
更新日期：2014-07-01 00:00:00
abstract：:Metastatic non-small-cell lung cancer is generally not considered to be curable, and the overall 5-year survival rate is less than 1%. Despite this poor prognosis, palliative chemotherapy can increase time and quality of life in the advanced-disease setting. New chemotherapy treatments and targeted therapies are avail...
journal_title：Clinical lung cancer
pub_type： 杂志文章
doi：10.1016/j.cllc.2011.06.007
更新日期：2011-11-01 00:00:00
abstract：INTRODUCTION:Patients with stage I small cell lung carcinoma (SCLC) are candidates for surgery; however, not much is known regarding the utilization of surgical resection in the management of stage I SCLC and the factors that determine the patient's ability to receive surgery. METHODS:The Surveillance, Epidemiology an...
journal_title：Clinical lung cancer
pub_type： 杂志文章
doi：10.1016/j.cllc.2017.03.003
更新日期：2017-09-01 00:00:00
abstract：:Bevacizumab is the first molecularly targeted agent associated with improved outcomes in combination with chemotherapy in previously untreated patients with non-small-cell lung cancer (NSCLC). The addition of bevacizumab, a monoclonal antibody against vascular endothelial growth factor (VEGF), to carboplatin and pacli...
journal_title：Clinical lung cancer
pub_type： 杂志文章,评审
doi：10.3816/CLC.2008.s.009
更新日期：2008-03-01 00:00:00
abstract：BACKGROUND:It is unclear what proportion of VTE events in lung cancer patients are incidentally discovered and whether incidental events affect mortality. PATIENTS AND METHODS:We conducted a retrospective cohort study of lung cancer patients seen at the University of Rochester between January 1, 2006 and December 31, ...
journal_title：Clinical lung cancer
pub_type： 杂志文章
doi：10.1016/j.cllc.2013.06.003
更新日期：2013-11-01 00:00:00
abstract：BACKGROUND:Central nervous system (CNS) progression is a common manifestation of acquired resistance to crizotinib in anaplastic lymphoma kinase (ALK)-rearranged non-small-cell lung cancer (NSCLC). However, an optimal tailored treatment approach has not been established in patients with CNS failure during crizotinib tr...
journal_title：Clinical lung cancer
pub_type： 杂志文章
doi：10.1016/j.cllc.2019.06.013
更新日期：2019-11-01 00:00:00
abstract：BACKGROUND:The optimal treatment strategy for locoregional recurrences developing after surgical resection in patients with non-small-cell lung cancer (NSCLC) is yet to be clearly established. PATIENTS AND METHODS:To investigate the efficacy and safety of radiotherapy (RT) and chemoradiotherapy (CRT), we reviewed the ...
journal_title：Clinical lung cancer
pub_type： 杂志文章
doi：10.1016/j.cllc.2017.05.005
更新日期：2017-11-01 00:00:00
abstract：:Traditionally, non-small-cell lung cancer (NSCLC) is not thought of as an immunosensitive malignancy. However, recent clinical results with GVAX, a granulocyte-macrophage colony-stimulating factor (GM-CSF) gene-transduced autologous tumor vaccine, may suggest otherwise. This review summarizes immune-induced activity c...
journal_title：Clinical lung cancer
pub_type： 杂志文章,评审
doi：10.3816/clc.2003.n.027
更新日期：2003-11-01 00:00:00
abstract：:The therapeutic options for patients with advanced non-small-cell lung cancer (NSCLC) are palliative. Therefore, the quality of life in oncology is considered as an endpoint in clinical trials, and several scales have been accepted for its measurement in parallel with other clinical determinations. However, its use in...
journal_title：Clinical lung cancer
pub_type： 杂志文章,评审
doi：10.3816/CLC.2009.n.010
更新日期：2009-03-01 00:00:00
abstract：INTRODUCTION:Prophylactic cranial irradiation (PCI) has proven to decrease the incidence of brain metastases (BMs), with a modest improvement in survival. PATIENTS AND METHODS:The impact of PCI was evaluated in 184 patients treated with chemoradiotherapy. PCI was applied to patients with disease with partial and compl...
journal_title：Clinical lung cancer
pub_type： 杂志文章
doi：10.1016/j.cllc.2016.11.005
更新日期：2017-07-01 00:00:00
abstract：INTRODUCTION:Frailty of surgical patients has been associated with worse outcomes. There is limited literature discussing frailty in patients with lung cancer treated with stereotactic body radiotherapy (SBRT). This study assesses the relationship between frailty and overall survival (OS), tumor control, and toxicity i...
journal_title：Clinical lung cancer
pub_type： 杂志文章
doi：10.1016/j.cllc.2018.05.008
更新日期：2018-09-01 00:00:00
abstract：:Thymic epithelial tumors are rare malignancies. Thymic carcinoma represents about 20% of all thymic epithelial tumors and has aggressive behavior, with a greater tendency to metastatic spread. Thymic carcinoma is often diagnosed in advanced stages for which systemic treatment is the main therapeutic option. The associ...
journal_title：Clinical lung cancer
pub_type： 杂志文章,多中心研究
doi：10.1016/j.cllc.2018.06.005
更新日期：2018-09-01 00:00:00
abstract：BACKGROUND:The level of N-terminal pro-B-type natriuretic peptide (NT-proBNP) is affected by many known factors. Our study aimed to evaluate whether other factors, in particular lung cancer, could be responsible for an increase in NT-proBNP levels in a population with no known risk factors for elevated NT-proBNP. PATI...
journal_title：Clinical lung cancer
pub_type： 杂志文章
doi：10.3816/CLC.2010.n.043
更新日期：2010-09-01 00:00:00
abstract：:Recent advances in cancer cell biology have led to the development of therapeutic agents that target pathways critical to the development and progression of disease. These so-called "targeted therapies" might offer patients a more tolerable alternative to traditional systemic chemotherapy that often achieves therapeut...
journal_title：Clinical lung cancer
pub_type： 杂志文章,评审
doi：10.3816/CLC.2006.n.037
更新日期：2006-09-01 00:00:00
abstract：:Active tumor immunotherapy may provide hope for patients with non-small-cell lung cancer (NSCLC) because, in more than 20 years, current therapies have yet to change mortality statistics. Creating an efficacious vaccine involves selection of important tumor antigens and formulation of their immunogenic epitopes into a...
journal_title：Clinical lung cancer
pub_type： 杂志文章,评审
doi：10.3816/clc.2008.s.003
更新日期：2008-02-01 00:00:00
abstract：:The International Lung Cancer Congress (ILCC), now in its ninth year, is a key forum for representatives of cooperative groups in North America, Europe, and Japan to discuss ongoing and planned clinical trials in lung cancer. Many of the significant strides in lung cancer treatment often originate from investigations ...
journal_title：Clinical lung cancer
pub_type：
doi：10.3816/CLC.2009.n.044
更新日期：2009-09-01 00:00:00
abstract：:The ability to reliably distinguish synchronous primary non-small-cell lung cancer (NSCLC) from intrapulmonary metastatic spread affects staging and treatment decisions in resected NSCLC. Adjuvant therapy for early-stage NSCLC is complicated and recommendations are primarily based on older data from trials that used n...
journal_title：Clinical lung cancer
pub_type： 杂志文章,评审
doi：10.1016/j.cllc.2015.03.004
更新日期：2015-09-01 00:00:00
abstract：BACKGROUND:Immune-related adverse events (irAEs) developed during immunotherapy with anti-PD-1 agents, could be a predictive surrogate marker of clinical benefit in patients with advanced non-small-cell lung cancer (NSCLC). METHODS:Patients with NSCLC, treated with anti-PD-1 agents, were retrospectively evaluated. Uni...
journal_title：Clinical lung cancer
pub_type： 杂志文章,多中心研究
doi：10.1016/j.cllc.2019.02.006
更新日期：2019-07-01 00:00:00
abstract：BACKGROUND:Patients with advanced non-small-cell lung cancer (NSCLC) and poor performance status (PS) are often excluded from trials. Gefitinib is a safe oral agent that may benefit these patients. PATIENTS AND METHODS:Seventy-two patients with poor PS and advanced NSCLC were enrolled onto this study of gefitinib 250 ...
journal_title：Clinical lung cancer
pub_type： 杂志文章,多中心研究
doi：10.3816/CLC.2005.n.028
更新日期：2005-09-01 00:00:00
abstract：:The treatment of lung cancer--small-cell lung cancer (SCLC) and non-small-cell lung cancer (NSCLC)--is a significant challenge in oncology. The best reported median survival remains near 1 year in advanced NSCLC despite several decades of steady improvement and extensive research with traditional chemotherapy drugs an...
journal_title：Clinical lung cancer
pub_type： 杂志文章,评审
doi：10.3816/clc.2005.s.002
更新日期：2005-09-01 00:00:00
abstract：:Both gemcitabine and carboplatin have demonstrated activity in advanced non small-cell lung cancer. The combination of gemcitabine and cisplatin has demonstrated equivalent or superior efficacy to other commonly used agents and two-drug combinations, and a recent Eastern Cooperative Oncology Group trial suggested that...
journal_title：Clinical lung cancer
pub_type： 杂志文章
doi：10.3816/clc.2000.s.008
更新日期：2000-12-01 00:00:00
abstract：:Randomized clinical trials (RCTs) of concurrent epidermal growth factor receptor-tyrosine kinase inhibitors (EGFR-TKIs) plus chemotherapy for unselected patients with advanced non-small-cell lung cancer (NSCLC) produced negative results. Intercalated administration could avoid the reduction of chemotherapy activity du...
journal_title：Clinical lung cancer
pub_type： 杂志文章,meta分析,评审
doi：10.1016/j.cllc.2016.08.006
更新日期：2017-01-01 00:00:00
abstract：UNLABELLED:Small observational studies have demonstrated an association between high ERCC1 expression level and poor prognosis in advanced NSCLC treated with platinum-based chemotherapy. This meta-analysis presents pooled estimates of association from 11 studies. High ERCC1 patients had lower response rates and higher ...
journal_title：Clinical lung cancer
pub_type： 杂志文章,评审
doi：10.1016/j.cllc.2011.04.005
更新日期：2011-11-01 00:00:00
abstract：BACKGROUND:Little is known about the difference between black and non-black patients with epidermal growth factor receptor (EGFR)-mutated non-small-cell lung cancer (NSCLC), particularly regarding survival. We thus characterized the EGFR expression profile, clinical characteristics, and survival outcome in these patien...
journal_title：Clinical lung cancer
pub_type： 杂志文章
doi：10.1016/j.cllc.2019.07.003
更新日期：2020-03-01 00:00:00
